Colchicine: Repositioning an “ancient” medicine in the 21st century DOI Creative Commons
Е. Л. Насонов, О. М. Драпкина

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 445 - 464

Published: Oct. 31, 2024

The main indications for colchicine treatment until recently were gout, pericarditis, familial Mediterranean fever and some other auto-inflammatory diseases. expansion of (repositioning) the use in direction prevention cardiovascular complications should be considered as one major events medicine XXI century. Deciphering role inflammation most important mechanism development atherosclerosis has created prerequisites concept anti-inflammatory therapy atherosclerosis, which low-dose can take an place, complementing effects aspirin, statins antihypertensive therapy. analysis materials from randomized placebo-controlled studies indicates a decrease frequency patients with coronary heart disease (by 31%) who have suffered myocardial infarction 23%), well 33%), stroke, need revascularization mortality. low dose (0.5 mg/day) is approved by U.S. Food Drug Administration disease. It assumed that future will place pathology associated atherosclerotic vascular

Language: Английский

Autoimmune diseases and atherosclerotic cardiovascular disease DOI
Florentina Porsch, Christoph J. Binder

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(11), P. 780 - 807

Published: June 27, 2024

Language: Английский

Citations

26
A Pairwise and Network Meta-analysis of Anti-inflammatory Strategies After Myocardial Infarction: the TITIAN study DOI Creative Commons
Claudio Laudani, Giovanni Occhipinti, Antonio Greco

et al.

European Heart Journal - Cardiovascular Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Abstract Background and aims Multiple anti-inflammatory drugs have been tested for secondary prevention after myocardial infarction (MI), giving mixed results questioning the efficacy of therapy. No head-to-head comparisons between performed. This study aimed to compare safety MI relative merits specific administration strategies. Methods Randomized trials therapy were identified. Primary endpoints trial-defined major adverse cardiovascular events (MACE) serious events. Secondary included all-cause death, individual MACE components, infection, cancer, gastrointestinal Pairwise meta-analyses conducted with interaction analyses drug type timing administration, in addition network meta-analyses. sensitivity meta-regression explore potential heterogeneity sources. Results Twenty-eight studies, involving 44 406 patients a mean follow-up 11 months, included. Anti-inflammatory reduced incidence (incidence rate ratio [IRR]: 0.92; 95% confidence interval [CI]: 0.86–0.98), without increasing However, it was associated higher (IRR: 1.21; CI: 1.07–1.36). significant observed effects on administration. Conclusions In MI, significantly reduces events, but is an increased risk

Language: Английский

Citations

1
Trends in Drug Repurposing: Advancing Cardiovascular Disease Management in Geriatric Populations DOI

Murali Krishna Moka,

Melvin George,

Deepalaxmi Rathakrishnan

et al.

Current Research in Translational Medicine, Journal Year: 2025, Volume and Issue: 73(2), P. 103496 - 103496

Published: Jan. 18, 2025

Language: Английский

Citations

1
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment DOI Creative Commons
Natalie Arnold, Wolfgang Köenig

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Targeting inflammation offers a unique possibility to address residual cardiovascular risk in almost two thirds of all patients with prevalent atherosclerotic disease (ASCVD). However, despite FDA approval and the ESC 2024 Guidelines for Management Chronic Coronary Syndrome recommendations implement low-dose colchicine (0.5 mg daily) secondary prevention ASCVD inflammatory risk, its clinical adoption is still limited. In this regard, simple screening elevated high-sensitive C-reactive protein (hsCRP) on routine basis might help recognize low-grade as an important therapeutic target. Within present review, we first provide recently published epidemiologic evidence that hsCRP at least strong predictor future events traditional lipoproteins. Furthermore, summarize our recent knowledge currently available strategies modulate process critically discuss open issues regarding benefit therapy acute coronary setting or stroke prevention. addition, also briefly touch upon some specific safety related long-term use colchicine. Finally, next diagnostic frontiers targeting such detection vascular/coronary by pericoronary fat attenuation ziltivekimab, human monoclonal antibody interleukin-6. Thus, integration interventions aimed lowering burden combination aggressive lipid-modifying may hold potential further reduce substantial ASCVD.

Language: Английский

Citations

1
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials DOI Creative Commons

Aernoud T.L. Fiolet,

Michiel H.F. Poorthuis, Tjerk S.J. Opstal

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 76, P. 102835 - 102835

Published: Oct. 1, 2024

Summary

Background

Guidelines recommend low-dose colchicine for secondary prevention in cardiovascular disease, but uncertainty remains concerning its efficacy stroke, key subgroups and about uncommon serious safety outcomes.

Methods

In this trial-level meta-analysis, we searched bibliographic databases trial registries form inception to May 16, 2024. We included randomised trials of ischaemic stroke major adverse events (MACE: myocardial infarction, coronary revascularisation, or death). Secondary outcomes were mortality. A fixed-effect inverse-variance model was used generate a pooled estimate relative risk (RR) with 95% confidence intervals (CI). This study is registered PROSPERO, CRD42024540320.

Findings

Six involving 14,934 patients prior disease included. all patients, compared placebo no reduced the by 27% (132 [1.8%] versus 186 [2.5%] events, RR 0.73 [95% CI 0.58–0.90]) MACE (505 [6.8%] 693 [9.4%] [0.65–0.81]). Efficacy consistent (females males, age below above 70, without diabetes, statin non-statin users). Colchicine not associated an increase outcomes: hospitalisation pneumonia (109 [1.5%] 106 [1.5%], 0.99 [0.76–1.30]), cancer (247 [3.5%] 255 [3.6%], 0.97 [0.82–1.15]), gastro-intestinal (153 [2.1%] 135 [1.9%]), 1.15 [0.91–1.44]. There difference all-cause death (201 [2.7%] 181 [2.4%], 1.09 [0.89–1.33]), (70 [0.9%] 80 [1.1%], 0.89 [0.65–1.23]), non-cardiovascular (131 101 [1.4%], 1.26 [0.98–1.64]).

Interpretation

MACE, treatment effect subgroups, did death.

Funding

funding source study.

Language: Английский

Citations

6
Enhanced Colchicine Production in Hairy Root Cultures of Gloriosa Superba L. Using Microbial Elicitors DOI

Pallavi Billowria,

Shajaat Hussain,

Nisha Kapoor

et al.

Indian Journal of Microbiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

Citations

0
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials DOI
Chunye Zhang, Shuai Liu, Yuxiang Sui

et al.

World Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 17(2)

Published: Jan. 18, 2025

The nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome is a critical modulator in inflammatory disease. Activation mutation of NLRP3 can cause severe inflammation diseases such as chronic infantile neurologic cutaneous articular syndrome, Muckle-Wells familial cold autoinflammatory syndrome 1. To date, great effort has been made to decode the underlying mechanisms activation. priming activation drive maturation release active interleukin (IL)-18 IL-1β pyroptosis, which significantly trigger many including diseases, immune disorders, metabolic neurodegenerative diseases. investigation therapeutic target for disease treatment hot topic both preclinical studies clinical trials. Developing potent inhibitors downstream IL-1 attracts wide-spectrum attention research pharmaceutical fields. In this minireview, we first updated molecular involved associated signaling pathways. We then reviewed cellular pathways obesity, diabetes, other addition, briefly roles cancer growth relative checkpoint therapy. Finally, trials with treatments targeting its were summarized.

Language: Английский

Citations

0
The Effect of Colchicine on Platelet Function Profiles in Patients with Stable Coronary Artery Disease: The ECLIPSE Pilot Study DOI Creative Commons
Naveen Seecheran,

Kathryn Grimaldos,

Penelope McCallum

et al.

Cardiology and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally once daily for 14 days on platelet reactivity with respect to aspirin reaction units (ARUs) and P2Y12 (PRUs). Twenty-two patients stable coronary artery disease (CAD) dual antiplatelet therapy (DAPT) maintenance clopidogrel were recruited. Baseline function was evaluated VerifyNow™ ARU PRU assays (Werfen, Bedford, MA, USA) post-completion COLC days. In this study, median baseline score 463, post-COLC it 436, which not statistically significant (p = 0.485). The mean difference in scores −18.31 (95% confidence interval [CI] −74.34 37.71, p 0.504). At baseline, 27.3% had "aspirin resistance" or non-responders, compared 13.6% 0.423). 210, 199, also 0.581). −7.31 CI −31.1 16.5, 0.530). 50% "clopidogrel 45.5% 0.999). Two experienced mild gastrointestinal upset during trial without interruption COLC, there no serious adverse events treatment-emergent events. There differences ARUs PRUs CAD. pilot could be clinically informative DAPT. Further studies are required confirm these exploratory findings. ClinicalTrials.gov identifier, NCT06567678, prospectively registered 20/8/2024.

Language: Английский

Citations

0
Colchicine in Cardiovascular Disease: Mechanisms of Action and Therapeutic Potential DOI

Shiuan‐Tzuen Su,

Yung‐Heng Lee,

James Cheng‐Chung Wei

et al.

International Journal of Rheumatic Diseases, Journal Year: 2025, Volume and Issue: 28(1)

Published: Jan. 1, 2025

Language: Английский

Citations

0
In-depth proteomic profiling identifies potentiation of the LPS response by 7-ketocholesterol DOI Creative Commons
Iain R. Phair,

Magdalena Sovakova,

Noor Alqurashi

et al.

Journal of Molecular and Cellular Cardiology Plus, Journal Year: 2025, Volume and Issue: 11, P. 100285 - 100285

Published: Jan. 29, 2025

In patients with stable coronary artery disease, plasma levels of 7-ketocholesterol (7-KC), found at high in atherosclerotic lesions, predict risk incident heart failure dose dependently, potentially contributing to disease aetiology. Previous studies demonstrated that 7-KC can elicit effects on macrophage function; however, the proteome have not been studied systematically. Here we used quantitative mass spectrometry establish effect mouse proteome. independently mediated dynamic changes, including atherogenic/M1 markers, cholesterol metabolism, biosynthesis and transport, as well nutrient transport more broadly. These changes were however insufficient alone drive cytokine chemokine secretion. Rather, they prime macrophage, potentiating LPS-stimulated TNF alpha secretion key pro-inflammatory enzymes. Our results indicate has independent metabolic macrophage; immune system are primarily due metabolism priming response an inflammatory stimulus. Earlier findings from CANTOS recent FDA approval colchicine highlight inflammation is a viable target for cardiovascular disease; it currrently unclear which will be best anti-inflammatory targets pursue future. this context, our suggest drugs targeting atherogenic markers induced by might tolerated, necessarily expected immunosuppressive.

Language: Английский

Citations

0